J. Forster

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.

S. Franco, S. Stein, K. Blackwell, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A study of prognostic factors for hepatic resection for colorectal metastases.

J. Forster, B. Langer, P. Greig, 1997, American journal of surgery.

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

M. Arbushites, S. Stein, K. Blackwell, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.

S. Franco, S. Stein, K. Blackwell, 2008, Annals of Oncology.

Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study

S. Ramalingam, Martin R. Weber, C. Belani, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.